Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.

A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Abstract Text:

    g lauxG Laux,e klieserE Klieser,h g schröderH G Schröder,v dittmannV Dittmann,b unterwegerB Unterweger,h schubertH Schubert,p königP König,h w schönyH W Schöny,j bunseJ Bunse,h beckmannH Beckmann,

    A double-blind multicentre study comparing the efficacy and safety of remoxipride in relation to haloperidol was conducted in 160 inpatients with schizophrenic illness diagnosed according to DSM-III. The study period was 4 weeks. The mean daily dose of remoxipride (whether given twice or three times daily) during the last week of treatment was 395 mg; the corresponding dose of haloperidol was 17 mg per day. No significant difference in therapeutic efficacy was found; Brief Psychiatric Rating Scale (BPRS) median total scores dropped from 41 to 20 (remoxipride twice daily, n = 51), 43 to 20 (remoxipride three times daily, n = 44) 40 to 19 (haloperidol three times daily, n = 48) at last valid rating. According to Clinical Global Impression (CGI) 68% in the remoxipride twice daily, 58% in the three times daily and 60% in the haloperidol group were very much or much improved. Treatment-emergent extrapyramidal checklist symptoms (hypokinesia, rigidity and tremor) were statistically significantly more frequent and more severe during haloperidol than during remoxipride treatment despite a statistically significantly higher concurrent use of anticholinergic drugs in the haloperidol group. Haloperidol treated patients reported more tiredness and drowsiness than remoxipride treated patients. Also, haloperidol treated patients had a significantly higher frequency of extrapyramidal symptoms on 8 out of 10 items of the Simpson and Angus scale.

    A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Publishing Authors By Initials

    g lauxG Laux,e klieserE Klieser,hg schröderHG Schröder,v dittmannV Dittmann,b unterwegerB Unterweger,h schubertH Schubert,p königP König,hw schönyHW Schöny,j bunseJ Bunse,h beckmannH Beckmann,

    For similar behavioral disciplines and activities: schizophrenic psychology research abstracts see: behavioral disciplines and activities: schizophrenic psychology research

    PUBMED ID PMID:

    MEDLINE DATE:

    A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Journal Published:

    PUBLICATION TYPE: Multicenter Study

    Journal: Acta psychiatrica Scandinavica. Supplementum

    VOLUME: 358

    Page Numbers: 125-9

    Journal Abbreviation:

    ISSN: 0065-1591

    DAY: 15

    MONTH: 02

    YEAR: 1990

    A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 370365

    A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Keywords Mesh Terms:

    KEYWORDS: Schizophrenic Psychology

    MESH TERMS: drug therapy

    Chemical & Substance for Abstract: A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia. Information

    Substance Name: Remoxipride

    Registry Number: 80125-14-0

    Grant and Affiliation Information for A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia.

    AFFILIATION: Department of Psychiatry, University of Würzburg, FRG.

    Country: DENMARK

    DENMARK Research PublicationDENMARK Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Acta Psychiatr Scand Suppl

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    A double-blind multicentre study comparing remoxipride, two and three times daily, with haloperidol in schizophrenia Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News